A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT ID: NCT03811561

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-08

Study Completion Date

2027-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Sponsor staff involved in the clinical trial is masked according to company standard procedures.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Semaglutide

Participants will receive semaglutide once weekly as subcutaneous (s.c., under the skin) injection added to standard of care.

Group Type EXPERIMENTAL

Semaglutide

Intervention Type DRUG

Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).

Placebo

Participants will receive placebo (semaglutide) once weekly as subcutaneous subcutaneous (s.c., under the skin) injection added to standard of care.

Group Type PLACEBO_COMPARATOR

Placebo (semaglutide)

Intervention Type DRUG

Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Semaglutide

Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).

Intervention Type DRUG

Placebo (semaglutide)

Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, age greater than or equal to 18 years at the time of signing informed consent
* Diagnosed with type 2 diabetes mellitus.
* HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).
* Early Treatment Diabetic Retinopathy Study (ETDRS) level of 10-75 (both inclusive) evaluated by fundus photography and confirmed by central reading centre
* No ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema six months prior to the day of screening.
* No anticipated need for ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema within three months after randomisation.
* Best-corrected visual acuity greater than or equal to 30 letters using the ETDRS visual acuity protocol
* No previous treatment with pan-retinal laser photocoagulation
* No substantial non-diabetic ocular condition that, in the opinion of the ophthalmologist, would impact diabetic retinopathy or diabetic macular oedema progression during the trial
* No substantial media opacities that would preclude successful imaging

Exclusion Criteria

* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
* Subjects presently classified as being in New York Heart Association (NYHA) Class IV
* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR less than 30 ml/min/1.73 m\^2
* Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
* Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
* Concurrent treatment with any GLP-1 receptor agonist or DPP-4 inhibitor from randomisation.
* Receipt of any investigational medicinal product within 30 days before screening
* Previous participation in this trial. Participation is defined as randomisation
* Known or suspected hypersensitivity to trial products or related products
* Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Reporting Anchor and Disclosure (1452)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Synexus Rsch /Cnt Phnx Med C

Phoenix, Arizona, United States

Site Status

Del Sol Research Management, LLC

Tucson, Arizona, United States

Site Status

South Arizona VA Healthcare System

Tucson, Arizona, United States

Site Status

Synexus Cln Rsrch Inc - Orange Gro FP

Tucson, Arizona, United States

Site Status

Southern California Res Ctr

Coronado, California, United States

Site Status

FDRC

Costa Mesa, California, United States

Site Status

Advanced Investigative Medicine, Inc.

Hawthorne, California, United States

Site Status

Diabetes/Lipid Mgmt & Res Ctr

Huntington Beach, California, United States

Site Status

Scripps Whittier Diabetes Inst

La Jolla, California, United States

Site Status

Torrance Clin Res Inst, Inc.

Lomita, California, United States

Site Status

Angel City Research, Inc.

Los Angeles, California, United States

Site Status

Downtown LA Res Ctr. Inc.

Los Angeles, California, United States

Site Status

Riverside University Health System Medical Center

Moreno Valley, California, United States

Site Status

Rancho Cucamonga Clinical Research

Rancho Cucamonga, California, United States

Site Status

Clinical Trials Research_Sacramento_0

Sacramento, California, United States

Site Status

UCLA Diabetes Center at Santa Monica

Santa Monica, California, United States

Site Status

Coastal Metabolic Research Center

Ventura, California, United States

Site Status

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Site Status

Barbara Davis Center

Aurora, Colorado, United States

Site Status

Rocky Mount Reg VA Med-DN

Aurora, Colorado, United States

Site Status

Chase Medical Research LLC

Waterbury, Connecticut, United States

Site Status

Innovative Research of W FL

Clearwater, Florida, United States

Site Status

Est Cst Inst for Rsrch,Jksnvil

Jacksonville, Florida, United States

Site Status

Reyes Clinical Research, Inc

Miami, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

Atlanta Diabetes Associates

Atlanta, Georgia, United States

Site Status

Endo Res Solutions Inc

Roswell, Georgia, United States

Site Status

Apex Medical Research Inc

Chicago, Illinois, United States

Site Status

The University Of Chicago

Chicago, Illinois, United States

Site Status

American Health Network of Indiana, LLC_Avon

Avon, Indiana, United States

Site Status

American Health Network of Indiana, LLC_Greenfield

Greenfield, Indiana, United States

Site Status

Iowa Diab & Endo Res Center

West Des Moines, Iowa, United States

Site Status

VA Medical Center

Lexington, Kentucky, United States

Site Status

Kentucky Diabetes-Endocrinology Center

Lexington, Kentucky, United States

Site Status

The Research Group of Lexington LLC

Lexington, Kentucky, United States

Site Status

L-MARC Research Center

Louisville, Kentucky, United States

Site Status

Four Rivers Clinical Research Inc

Paducah, Kentucky, United States

Site Status

MedStar Hlth Res Institute

Hyattsville, Maryland, United States

Site Status

Brigham & Women's Hospital

Boston, Massachusetts, United States

Site Status

Boston Medical Center_Cary

Boston, Massachusetts, United States

Site Status

Joslin Center For Diabetes

Boston, Massachusetts, United States

Site Status

Joslin Diabetes Center

Boston, Massachusetts, United States

Site Status

Michigan Medicine

Ann Arbor, Michigan, United States

Site Status

Synexus Clinical Research US, Inc._Tempe_0

Richfield, Minnesota, United States

Site Status

Diabetes & Endo Specialists Inc

Chesterfield, Missouri, United States

Site Status

Palm Research Center Inc-Vegas

Las Vegas, Nevada, United States

Site Status

Southern New Hampshire Diabete

Nashua, New Hampshire, United States

Site Status

Lovelace Scientific Resources Inc

Albuquerque, New Mexico, United States

Site Status

University of New Mexico

Albuquerque, New Mexico, United States

Site Status

NYC Research, Inc.

New York, New York, United States

Site Status

Mountain Diabetes & Endocrine Center

Asheville, North Carolina, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

OnSite Clinical Solutions, LLC

Charlotte, North Carolina, United States

Site Status

Your Diabetes Endocrine Nutrition Group, Inc.

Mentor, Ohio, United States

Site Status

University of Toledo Medical Center

Toledo, Ohio, United States

Site Status

Harold Hamm Diabetes Center

Oklahoma City, Oklahoma, United States

Site Status

Aria Endocrine Metabolic Assoc

Philadelphia, Pennsylvania, United States

Site Status

Tristar Clin Investigations, PC

Philadelphia, Pennsylvania, United States

Site Status

Holston Medical Group Pc

Bristol, Tennessee, United States

Site Status

Univ Diab & Endo Consultants

Chattanooga, Tennessee, United States

Site Status

Holston Medical Group

Kingsport, Tennessee, United States

Site Status

Vanderbilt Diab Obes Clin Tri

Nashville, Tennessee, United States

Site Status

Central Texas Clinical Research

Austin, Texas, United States

Site Status

Texas Diab & Endo, P.A.

Austin, Texas, United States

Site Status

Velocity Clinical Res-Dallas

Dallas, Texas, United States

Site Status

UT Southwestern Med Cntr

Dallas, Texas, United States

Site Status

Clinical Trials of Texas, LLC

San Antonio, Texas, United States

Site Status

VIP Trials

San Antonio, Texas, United States

Site Status

Consano Clinical Research, LLC

Shavano Park, Texas, United States

Site Status

Simcare Medical Research, LLC

Sugar Land, Texas, United States

Site Status

Synexus Clinical Research US, INC.

Murray, Utah, United States

Site Status

MultiCare Inst for Res & Innov

Spokane, Washington, United States

Site Status

CPQuali Pesquisa Clínica Ltda

São Paulo, São Paulo, Brazil

Site Status

DCC I- Pleven EOOD Endocrinology

Pleven, , Bulgaria

Site Status

MHAT Sveti Pantaleimon - Pleven, Internal Diseases

Pleven, , Bulgaria

Site Status

MHAT Med Line Clinic

Plovdiv, , Bulgaria

Site Status

UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Endocrinology

Plovdiv, , Bulgaria

Site Status

MHAT MC-Sv Ivan Rilski EOOD

Plovdiv, , Bulgaria

Site Status

"DCC VII - Sofia", Endocrinology Consulting Room

Sofia, , Bulgaria

Site Status

DCC VII - Sofia EOOD, Endocrinology

Sofia, , Bulgaria

Site Status

MHAT Knyaginya Klementina - Sofia EAD

Sofia, , Bulgaria

Site Status

USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

Sofia, , Bulgaria

Site Status

IV MHAT - Sofia EAD

Sofia, , Bulgaria

Site Status

"DCC XX - Sofia" EOOD, Endocrinology Consulting Room

Sofia, , Bulgaria

Site Status

Medical centre Vitclinic EOOD

Sofia, , Bulgaria

Site Status

Alberta Diabetes Institute

Edmonton, Alberta, Canada

Site Status

LMC Clinical Res Thornhill

Concord, Ontario, Canada

Site Status

LMC Endo Ctr (Etobicoke) Ltd

Etobicoke, Ontario, Canada

Site Status

LMC Oakville

Oakville, Ontario, Canada

Site Status

The Ottawa Hospital_Riverside

Ottawa, Ontario, Canada

Site Status

LMC Endo Centres Ltd.(Bayview)

Toronto, Ontario, Canada

Site Status

LMC Clinical Research, Inc. (Montreal Glen)

Montreal, Quebec, Canada

Site Status

Centricity Res Pointe-Claire

Pointe-Claire, Quebec, Canada

Site Status

LMC Clin Rsrch Inc. (Montreal)

Saint-Laurent, Quebec, Canada

Site Status

Fakultni nemocnice Brno

Brno, , Czechia

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Diabetologie Krupska

Prague, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady_Praha

Prague, , Czechia

Site Status

Institut klinicke a experimentalni mediciny

Prague, , Czechia

Site Status

MUDr. Michala Pelikanova

Prague, , Czechia

Site Status

Praxis Denger/Pfitzner, Friedrichsthal

Friedrichsthal, , Germany

Site Status

Diabetologische Schwerpunktpraxis Harburg- Dr. med.Paschen,

Hamburg, , Germany

Site Status

Diabetes-Zentrum-Wilhelmsburg GbR

Hamburg, , Germany

Site Status

Wendisch/Dahl Hamburg (DZHW)

Hamburg, , Germany

Site Status

Wendisch/Dahl Hamburg

Hamburg, , Germany

Site Status

Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

Münster, , Germany

Site Status

MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin

Münster, , Germany

Site Status

Praxis Dr. med. Wenzl-Bauer

Rehlingen-Siersburg, , Germany

Site Status

Zentrum für klinische Studien Alexander Segner

Saint Ingbert-Oberwürzbach, , Germany

Site Status

University Hospital of Athens ATTIKON

Athens, Attica, Greece

Site Status

Iatriko Psychicou Private Clinic

Athens, , Greece

Site Status

"Laiko" General Hospital of Athens

Athens, , Greece

Site Status

"Laiko" General Hospital of Athens

Athens, , Greece

Site Status

Iatriko Athinon 'Palaiou Falirou'

Athens, , Greece

Site Status

University Hospital of Athens ATTIKON

Haidari-Athens, , Greece

Site Status

"Ippokrateio" G.H. of Thessaloniki

Thessaloniki, , Greece

Site Status

"Thermi" Private Hosital

Thessaloniki, , Greece

Site Status

"Thermi" Private Hosital

Thessaloniki, , Greece

Site Status

Endolife Specialty Hospitals

Guntur, Andhra Pradesh, India

Site Status

Nirmal Hospital Pvt. Ltd.

Surat, Gujarat, India

Site Status

Narayana Hrudayalya Institute of Cardiac Sciences

Bangalore, Karnataka, India

Site Status

Diacon Hospital Private Limited

Bangalore, Karnataka, India

Site Status

Amrita Institute Of Medical Sciences & Research Centre

Kochi, Kerala, India

Site Status

Indian Institute of Diabetes

Thiruvananthapuram, Kerala, India

Site Status

Indian Institute of Diabetes

Thiruvnanthapuram, Kerala, India

Site Status

BYL Nair Hospital and T N Medical College Department of endo

Mumbai, Maharashtra, India

Site Status

Seth GS medical college and KEM Hospital

Mumbai, Maharashtra, India

Site Status

Government Medical College and Super Speciality Hospital, Nagpur

Nagpur, Maharashtra, India

Site Status

DEW Medicare & Trinity hospital

Nagpur, Maharashtra, India

Site Status

Deenanath Mangeshkar Hospital & Research Centre

Pune, Maharashtra, India

Site Status

All India Institute of Medical Sciences

Ansari Nagar, New Delhi 110029, New Delhi, India

Site Status

Apollo Hospital

Delhi, New Delhi, India

Site Status

Indraprastha Apollo Hospital

Delhi, New Delhi, India

Site Status

All India Institute of Medical Sciences

New Dehli, New Delhi, India

Site Status

Dayanand Medical College & Hospital_Ludhiana

Ludhiana, Punjab, India

Site Status

Christian Medical College and Hospital

Ludhiana, Punjab, India

Site Status

Madras Diabetes Research Foundation

Chennai, Tamil Nadu, India

Site Status

Arthur Asirvatham hospital,

Madurai, Tamil Nadu, India

Site Status

SSKM

Kolkata, West Bengal, India

Site Status

Apollo Gleneagles Hospital

Kolkata, West Bengal, India

Site Status

Apollo Multispeciality Hospital, Kolkata

Kolkata, West Bengal, India

Site Status

Care Hospital

Hyderabad, , India

Site Status

Aditya Jyot Hospital

Mumbai, , India

Site Status

Rambam MC - Diabetes and obesity center of excellence

Haifa, , Israel

Site Status

Hadassah Ein Karam MC - Diabetes Unit

Jerusalem, , Israel

Site Status

Meir MC - Diabetes unit

Kfar Saba, , Israel

Site Status

Rabin MC Beilinson - Endo unit

Petah Tikva, , Israel

Site Status

Sourasky MC - Institute of Endocrinology, metabolism and hypertension

Tel Aviv, , Israel

Site Status

Sheba MC - Endocrinology Clinic

Tel Litwinsky, , Israel

Site Status

Zemgales diabetes centre

Jelgava, , Latvia

Site Status

Teterovska practice

Ogre, , Latvia

Site Status

P. Stradins Clinical University Hospital

Riga, , Latvia

Site Status

Medical Centre Pulss 5

Riga, , Latvia

Site Status

Juglas Medicine Center

Riga, , Latvia

Site Status

Instituto Nacional de Nutricion - Unidad de Inv de Enf Metab

Distrito Federal, México, D.F., Mexico

Site Status

Hospital Universitario Dr. José Eleuterio González_Monterrey

Monterrey, Nuevo León, Mexico

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, Podlaskie Voivodeship, Poland

Site Status

In-Vivo Sp. z o.o.

Bydgoszcz, , Poland

Site Status

B_Serwis Popenda Sp.J.

Chorzów, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Gdansku

Gdansk, , Poland

Site Status

NZOZ Gdanska Poradnia Cukrzycowa Sp.z o.o.

Gdansk, , Poland

Site Status

Centrum Medyczne Pratia Katowice

Katowice, , Poland

Site Status

Clinical Medical Research Korfantego - Ambulatoryjna Opieka

Katowice, , Poland

Site Status

FutureMeds Sp. z o.o.

Krakow, , Poland

Site Status

Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia

Lodz, , Poland

Site Status

Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.

Lodz, , Poland

Site Status

Prywatny Gabinet Lekarski Jan Ruxer

Lodz, , Poland

Site Status

NZOZ "DiabMed" Poradnia Diabetologiczna

Poznan, , Poland

Site Status

Gaja Poradnie Lekarskie

Poznan, , Poland

Site Status

SPZZOZ im. Marszalka J. Pilsudskiego w Plonsku

Płońsk, , Poland

Site Status

SPSK nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach, ul. 3-go Maja 13/15 41-800 Zabrze

Zabrze, , Poland

Site Status

Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia

Lodz, Łódź Voivodeship, Poland

Site Status

ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

Senhora Da Hora, Matosinhos, Matosinhos, Portugal

Site Status

ULS Almada-Seixal E.P.E. - Hospital Garcia de Orta

Almada, , Portugal

Site Status

ULS Da Regiao De Aveiro E.P.E. - Hospital Infante D. Pedro

Aveiro, , Portugal

Site Status

Unidade Local de Saúde de Coimbra, E.P.E.

Coimbra, , Portugal

Site Status

ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães

Guimarães, , Portugal

Site Status

APDP - Associação Protectora dos Diabéticos de Portugal

Lisbon, , Portugal

Site Status

Centro Hospitalar de São João

Porto, , Portugal

Site Status

Unidade Local de Saude de Sao Joao E.P.E

Porto, , Portugal

Site Status

ULS Da Arrábida, E.P.E._Hospital de São Bernardo

Setúbal, , Portugal

Site Status

Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

Bucharest, Bucurestii, Romania

Site Status

Clinic of Diabetes Cluj

Cluj-Napoca, Cluj, Romania

Site Status

SC Centru Medical Dr. Negrisanu SRL

Timișoara, Timiș County, Romania

Site Status

3rd Clinic for Nutrition-Spitalulul Județean de Urgenta

Timișoara, Timiș County, Romania

Site Status

"Carol Davila" Military Emergency Hospital

Bucharest, , Romania

Site Status

Sana Monitoring SRL

Bucharest, , Romania

Site Status

SC Clinica Diabnutrimed S.R.L.

Bucharest, , Romania

Site Status

Multispecialty Medical Clinic Anturium LLC

Barnaul, , Russia

Site Status

Kazan Federal University

Kazan', , Russia

Site Status

PIH "Clin Hosp "RZD-Medicina" former Kazan OJSC Rus Railways

Kazan', , Russia

Site Status

Kazan Federal University

Kazan', , Russia

Site Status

FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia

Moscow, , Russia

Site Status

National Medical Research Center of Endocrinology

Moscow, , Russia

Site Status

Branch of limited liability company "Hadassah Medical LTD"

Moscow, , Russia

Site Status

State Novosibirsk regional clinical hospital

Novosibirsk, , Russia

Site Status

City Consultative & Diagnostic Centre #1

Saint Petersburg, , Russia

Site Status

Diagnistic Centre "Energo"

Saint Petersburg, , Russia

Site Status

Consultative & Diagnostic Center with a Outpatient Hospital

Saint Petersburg, , Russia

Site Status

Llc "International Medical Center "Time"

Saint-Peterburg, , Russia

Site Status

SHI Saratov City Clinical Hospital #9

Saratov, , Russia

Site Status

Regional clinical cardiology dispensary

Saratov, , Russia

Site Status

Sverdlovsk Regional Clinical Hospital #1

Yekaterinburg, , Russia

Site Status

Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.

Novi Sad, Vojvodina, Serbia

Site Status

CHC Zvezdara, Clinical department for endocrinology

Belgrade, , Serbia

Site Status

Endocrinology, Diabetes and Metabolism Diseases Clinic

Belgrade, , Serbia

Site Status

Clinical Hospital Center Bezanijska Kosa

Belgrade, , Serbia

Site Status

Clinical Centre Nis, Endocrinology, Diabetes and Metabolism

Niš, , Serbia

Site Status

V. interna klinika LF UK a UNB

Bratislava, , Slovakia

Site Status

Nemocnica akademika L. Derera, UNB

Bratislava, , Slovakia

Site Status

Diabetologicka ambulancia, Dia Zilina s.r.o.

Žilina, , Slovakia

Site Status

Medivasa s.r.o., Diabetologicka ambulancia

Žilina, , Slovakia

Site Status

MEDIVASA, s.r.o., Diabetologicka ambulancia

Žilina, , Slovakia

Site Status

Complejo Hospitalario Universitario A Coruña

A Coruña, , Spain

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital de Bellvitge

L'Hospitalet de Llobregat, , Spain

Site Status

Clinica Universitaria de Navarra

Pamplona, , Spain

Site Status

Hospital Virgen de la Macarena

Seville, , Spain

Site Status

Hospital La Fe - Endocrinología y Nutrición

Valencia, , Spain

Site Status

Harrogate District Hospital

Harrogate, North Yorkshire, United Kingdom

Site Status

Queen's Medical Centre University Hospital

Nottingham, Nottinghamshire, United Kingdom

Site Status

University Hospital, Queens Medical Centre

Nottingham, Nottinghamshire, United Kingdom

Site Status

Yeovil District Hospital - Clinical Research Unit

Yeovil, Somerset, United Kingdom

Site Status

Kings College Hospital

London, , United Kingdom

Site Status

Norfolk and Norwich University Hospital

Norfolk, , United Kingdom

Site Status

George Eliot Hospital NHS Trust

Nuneaton, , United Kingdom

Site Status

George Eliot Hospital

Nuneaton, , United Kingdom

Site Status

Clinical Research Unit

Somerset, , United Kingdom

Site Status

Royal Cornwall Hospital (Treliske)

Truro, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Brazil Bulgaria Canada Czechia Germany Greece India Israel Latvia Mexico Poland Portugal Romania Russia Serbia Slovakia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1201-6256

Identifier Type: OTHER

Identifier Source: secondary_id

2017-003619-20

Identifier Type: REGISTRY

Identifier Source: secondary_id

NN9535-4352

Identifier Type: -

Identifier Source: org_study_id